media – Page 620 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

AstraZeneca’s Imfinzi gets speedy US review for lung cancer

US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi (durvalumab) to include patients with a certain form of lung cancer.
- Source: Pharmatimes
- 788
- October 18, 2017
AstraZeneca FDA Imfinzi (durvalumab) lung cancer
Medical Monitoring Device Maker MagicMed Bags USD1.5 Million in Pre-Series A Financing

Medical equipment maker MagicMed Technologies (Beijing) Co. has secured USD1.5 million (CNY10 million) in pre-series A financing. The funds will help the firm hasten the commercialization of its Magitor Cell, a single channel electrocardiographic monitoring device.
- Source: Yicaiglobal
- 414
- October 18, 2017
MagicMed Technologies Magitor Cell Series
AI could bring £630bn to UK by 2035

The review, led by Jerome Pesenti, chief executive of BenevolentTech and Dame Wendy Hall, Professor of Computer Science at the University of Southampton, says AI is expected to make “great improvements” for the public, including more personalised services, better healthcare and more efficient use of resources.
- Source: Pharmatimes
- 479
- October 17, 2017
Artificial Intelligence Industrial Strategy
US researchers develop surgical implant to accommodate child growth

Researchers from Harvard Medical School, Boston Children’s Hospital and Brigham and Women’s Hospital in the US have developed a paediatric surgical implant that grows along with the child.
- Source: medicaldevice-network
- 474
- October 17, 2017
heart valve defects paediatric surgical implan
FDA panel votes in favor of Spark’s blindness gene therapy

Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.
- Source: cnbc
- 1,028
- October 17, 2017
Company Insight gene inherited therapy
InflaRx announces a $ 55M Series D financing and investment round

InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced a $ 55M Series D financing and investment round.
- Source: inflarx.de
- 585
- October 17, 2017
Market Views Series therapeutics
Warp Drive Bio Forms Strategic Collaboration to Advance Novel Classes of Antibiotics

Warp Drive Bio, Inc., a drug discovery company developing therapeutics that exploit the molecules and mechanisms of nature, announced today that it has formed a strategic collaboration with Roche to discover and develop multiple novel classes of antibiotics. The serious global health threat of multi-drug-resistant bacterial infections has created an urgent need for new antibiotics with novel structures and mechanisms of action.
- Source: Businesswire
- 429
- October 17, 2017
antibiotics infections Market Views
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated.
- Source: Pfizer
- 692
- October 17, 2017
Clinical Trials inhibitor Phase tyrosine kinase
NICE flip-flops to back Bristol’s Opdivo in head and neck cancer despite data ‘uncertainties’

Back in April, England’s cost watchdogs said they wouldn’t cover Bristol-Myers Squibb’s Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now, though, they’re singing a different tune.
- Source: Fiercepharm
- 552
- October 16, 2017
New Approvals NHS Opdivo
Ebola vaccines from GSK, Merck elicit yearlong response, study finds

After initially setting out to test two vaccines on 28,000 volunteers during West Africa's deadly Ebola epidemic, a U.S.-Liberia research team had to dramatically reduce its aspirations when the outbreak started coming to an end. But the investigators have now published results showing the shots from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination.
- Source: Fiercepharma
- 802
- October 16, 2017
aspirations Clinical Trials Ebola

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.